Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals and keeping the price target at $9.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors including Armata Pharmaceuticals’ recent positive clinical trial results and strategic plans for future development. The company reported successful outcomes from its Phase 1b/2a diSArm trial, which evaluated the efficacy of AP-SA02 in treating S. aureus bacteremia. The trial met all its primary endpoints, demonstrating significant clinical response rates and a strong safety profile, which are promising indicators for the drug’s potential success.
Furthermore, Armata is preparing for an end-of-Phase 2 meeting with the FDA, aiming to align on the design of a subsequent Phase 3 trial. This forward-looking strategy, coupled with the encouraging trial data, suggests a positive trajectory for the company’s future developments. These factors contribute to Pantginis’s optimistic outlook and support his Buy rating for Armata Pharmaceuticals’ stock.